Published February 6, 2024 | Version v1

Ipilimumab and nivolumab first-line therapy in BRAF-mutated metastatic melanoma patients is protective for the occurrence of new brain metastasis.

Authors/Creators

Description

5-years OS, TPFS, BMFS, SABM and biomakers of SECOMBIT trial.

Files

Files (28.0 kB)

Name Size Download all
md5:dcd7ebb9851bda0f71bfa4cee58069ef
28.0 kB Download

Additional details

Dates

Updated
2024-02-06